Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis

Zamorskii II, Shchudrova TS, Lin'kova NS, Nichik TE, Khavinson VKh. Bull Exp Biol Med. 2017.

Organ: liver-metabolic · Type: in-vivo · Peptides: EDL

In two rat models of acute kidney injury (gentamicin and ischemia/reperfusion), the authors report that EDL lessened oliguria, azotemia, proteinuria, and sodium wasting and supported antioxidant enzymes.

Editorial summary of a 2017 short experimental paper in Bulletin of Experimental Biology and Medicine. Animal work only. Public pages cite PubMed only. Read the paper: PMID 28744634.

Methods

Two series in random-bred albino rats (150–200 g; n = 42; seven animals per group), reported as compliant with EU Directive 2010/63/EU. Series I: gentamicin sulfate 80 mg/kg daily for six days, with or without EDL 3 μg/kg intraperitoneally 40 minutes after each gentamicin dose; animals were sampled 24 hours after the last dose. Series II: sham operation versus 60-minute bilateral renal-pedicle clipping and 24-hour reperfusion, with EDL 3 μg/kg for three days before ischemia in the treated group. The authors measured diuresis, plasma creatinine and creatinine clearance, urinary protein, fractional sodium excretion and sodium reabsorption, plus kidney-tissue MDA, catalase, glutathione peroxidase, and succinate dehydrogenase. Protocol numbers belong in the primary text; this page does not reprint the publisher tables.

Findings

The authors report that gentamicin and ischemia/reperfusion each produced oliguria, azotemia, proteinuria, and increased fractional sodium excretion, with higher tissue MDA and lower catalase, GPx, and SDH activity. In both models they report that EDL lessened those functional changes (higher diuresis and creatinine clearance; lower proteinuria and sodium wasting) and moved the oxidative and energy markers toward control values. They interpret this as a nephroprotective effect on tubular and glomerular injury of toxic and ischemic origin in the rat, and they call for further study.

This is a single in-vivo communication in rats. It is not a clinical trial, not a human dosing guide, and not a product claim. Independent replication and human evidence are separate questions; they are not answered by this paper. Follow the PMID.